S

South Florida Research Institute | Lauderdale Lakes, FL

Research site

(Unclaimed)

Location

2951 NW 49th Avenue Suite 101, Lauderdale Lakes, Florida, United States of America

Site insights

Top conditions

Top treatments

Bardoxolone Methyl

Tenapanor

Selonsertib

BI 690517

Iron

INV-202

ADX-629

GS-4997

BI 685509

PF-07321332

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 20 total trials

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserv...

Enrolling

Immunoglobulin A Nephropathy

Drug: Placebo (matched to Povetacicept)

Drug: Povetacicept

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147

Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease (AMPLIFIED)

The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated ki...

Enrolling

Proteinuric Kidney Disease

Drug: Inaxaplin

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in...

Active, not recruiting

Immunoglobulin A Nephropathy

Drug: Sibeprenlimab 400 mg

Drug: Placebo